PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living with Retroviral Infection in Liberia (HONOR) by Moses, J. Soka et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
PEER Liberia Project UMass Medical School Collaborations in Liberia 
2019-2 
PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic 
Monitoring Study of People Living with Retroviral Infection in 
Liberia (HONOR) 
J. Soka Moses 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/liberia_peer 
 Part of the Clinical Epidemiology Commons, Epidemiology Commons, Family Medicine Commons, 
Infectious Disease Commons, International Public Health Commons, Medical Education Commons, and 
the Virus Diseases Commons 
Repository Citation 
Moses J, Wachekwa I, Migueles SA. (2019). PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic 
Monitoring Study of People Living with Retroviral Infection in Liberia (HONOR). PEER Liberia Project. 
https://doi.org/10.13028/scq9-dr48. Retrieved from https://escholarship.umassmed.edu/liberia_peer/16 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in PEER Liberia Project by 
an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
PREVAIL VIII:
A CoHOrt Clinical, Viral, and 
ImmuNOlogic Monitoring Study of 
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Stephen A. Migueles, MD
Background: HIV Prevalence and Risk Groups
▪ >25.6 million PLHIV in Sub-Saharan Africa (36.7 
million worldwide) 
AIDS-related deaths declining 
globally, but increased in Western/ 
Central Africa in 2013 to 36%
In 2016, 310,000 deaths in this region in 2016 (UNAIDS, 
2017).
Background: HIV Prevalence and Risk Groups
▪ Little is known about the nature of the HIV epidemic 
in Liberia.
▪ HIV prevalence in Liberia increased from 1.5% in 
2007 to 2.1% in 2013 in the general population aged 
15-49 years despite increases in the numbers of 
centers providing ART (LISGIS, LDHS 2013, 2014).
▪ 43,000 PLHIV
▪ 2.6% urban, 0.8% rural
▪ 2.4% women versus 1.9% men
▪ Increased in almost all age groups
▪ High risk/prevalence populations (IBBSS, 2013)
▪ MSM 19.8%
▪ FSW 9.8%
▪ Uniform Service personnel 5%
▪ Transport workers, traders 4.8%, 4.6%
▪ IDU 3.9%
▪ Lowest: youth in schools 1.1%
Background: HIV Prevalence and Risk Groups
In PREVAIL I, HIV prevalence of 1,500 study participants in Monrovia 
was 5.2% and only 0.6% reported being aware that they were infected 
with HIV (Kennedy et al., N Eng J Med, 2017)
Background: ART
▪ 18.7% on ART (National AIDS Commission Liberia, 2017) 
▪ 69% pregnant women annually prescribed ARVs
▪ Available ARV regimens
▪ 1st line: Tenofovir, lamivudine, zidovudine, efavirenz, nevirapine
▪ 2nd line/HIV-2: Abacavir, lopinavir/ritonavir
▪ 2014 Integrated Guidelines for Prevention, Testing, Care 
and Treatment of HIV/AIDS in Liberia
▪ ART initiation recommended for patients with WHO stages III or IV or 
asymptomatic patients with CD4 counts 500 cells/mm3
▪ Goals: “reduce morbidity and mortality by aggressively suppressing 
viral load, and preventing and treating OIs…maximize the benefits of 
treatment by encouraging consistent adherence to ART”
Background: ART Resistance
▪ Transmitted ARV resistance mutations among newly diagnosed 
patients at JFK and Redemption (Loubet et al., 2014)
▪ CRF02_AG 66%
▪ N=116 (85 women): 5.9% (CI: 1.7-10.1)
▪ Acquired resistance in those failing 1st line defined by clinical or 
immunologic parameters (Loubet et al., 2015)
▪ N=90; ART>1 year (median 42 months)
▪ 27% were <50 copies/mL; median pVL=4.7 log10 copies/mL
▪ RAMs: NRTI 63%, NNRTI 71%
▪ Most prevalent → 3TC/FTC, NVP and EFV
▪ Virologic monitoring is needed.
Background: Challenges
▪ Widespread norm of multiple and concurrent sexual relationships
▪ Increasing poverty leading to sex work
▪ Low condom use
▪ 19.5% of MSM during anal intercourse (LHARPR, 2016)
▪ High incidence of STIs
▪ Widespread stigma, with some population particularly vulnerable, 
e.g., young girls, MSM and FSW
▪ Low comprehensive HIV/AIDS knowledge
▪ Limited access to HIV testing, measurements of CD4 counts and 
viral load, and ART
▪ Unclear actual burden/nature of the HIV/AIDS epidemic in Liberia 
▪ Lack of awareness of HIV status
▪ Underutilization of services
▪ Low retention in care; higher for those on ART
▪ Fragile health system despite efforts to scale up
▪ Shortages of trained staff
Rationale for HIV Study
• Knowledge gaps 
▪ High quality scientific research is fill the 
knowledge gap
▪ Provide a clearer understanding of the HIV 
epidemic in Liberia 
▪ Improve health and clinical follow-up of people 
living with HIV/AIDS
▪ Support policy and care through collaborative 
research
▪ Improve capabilities for independent research
Importance of the Study
HONOR Study Objectives
• Primary Objectives
– Describe the major sociodemographic, clinical, 
immunologic and virologic characteristics of HIV disease in 
the study population at baseline.
– Describe the course of HIV disease in the study population 
as a whole or by sub-group
• Secondary objectives
– Prevalence and patter of HIV resistance at various time 
points during the study
– Facilitate future research.
HONOR Study Objectives
Objective Characteristics/Outcome Measures 
Describe major social/demographic, 
clinical, immunologic, and virologic 
characteristics of HIV disease in the study 
population at baseline. 
• New or prior diagnosis of HIV-1/2 
• WHO HIV/AIDS clinical stage (I-IV)a 
• Gender 
• Age 
• HIV risk factorsb 
• Prior Ebola virus infection 
• Blood pressure 
• Body mass index and pediatric age-for-
length percentiles 
• CD4 count 
• Plasma HIV-1 RNA level 
• ARV treatment status (duration, first- or 
second-line regimen, virally suppressed at 
enrollment) 
• History of ARV toxicity/intolerance  
• Prior or current 
trimethoprim/sulfamethoxazole 
(TMP/SMX) prophylaxis 
• Prior or current opportunistic diseasec 
• Prior or current STIsd 
• Prior or current other co-infectionse 
• Prior or current non-AIDS comorbiditiesf 
• Pregnancies 
• Highest education level 
• Employment status 
• Occupation 
• Marital status 
• Number of sexual partners 
• Condom use 
• Alcohol use 
• Tobacco use 
• Internalized AIDS-Related Stigma Scale 
Describe the course of HIV disease in the 
study population as a whole or by sub-
group. 
 
Longitudinal measures include, but are not 
limited to: 
• Alcohol use 
• Tobacco use 
• Number of sexual partners 
• Blood pressure 
• Body mass index and pediatric age-for-
length percentiles 
• CD4 counts 
• HIV-1 RNA levels (including percent of 
time suppressed below the lower 
detection threshold, number of viral 
blips) 
• ARV regimen modifications 
• Hospitalizations 
• Biomarker levelsg 
Incidence of the following collected by self 
report, from medical record review or from 
testing in the current protocol: 
• Opportunistic diseasesc 
• STIsd,h 
• Other co-infectionse,i  
• Non-AIDS comorbiditiesf,j  
• Death 
• Pregnancy 
 a www.who.int/hiv/pub/guidelines/clinicalstaging.pdf. 
b MSM, heterosexual, sex workers, intravenous drug use, blood transfusion, perinatal, unknown, other. 
c We will collect the opportunistic diseases listed by the U.S. Centers for Disease Control and Prevention at 
https://www.cdc.gov/hiv/basics/livingwithhiv/opportunisticinfections.html. 
d Syphilis, gonorrhea, chlamydia, Trichomonas vaginalis, herpes simplex virus, chancroid. 
e Hepatitis B virus, hepatitis C virus, malaria, bacterial pneumonia, any infection requiring clinical evaluation/care. 
f Cardiovascular, renal, hepatic, or serious non-AIDS malignancies. 
g d-dimer, high-sensitivity C-reactive protein, interleukin-6. 
h Gonorrhea, chlamydia and syphilis testing will be performed in this study at baseline, yearly and when clinically 
indicated.  
i Hepatitis B surface antigen, core antibody, e antigen, surface antibody, and viral load testing will be performed at 
baseline and repeated yearly if not previously resulted as positive. 
j The CKD-EPI creatinine equation will be used to estimate GFR and stage disease, if present. 
 
Objective Outcome Measures 
Determine the prevalence and patterns of 
ARV resistance at various timepoints during 
the study period. 
Determine ARV genotypic resistance 
mutations within 1 year of study initiation on 
stored samples from a subset of participants 
with HIV-1 RNA >1000 copies/mL at 
baseline (+/- ART) or at other early study 
time points.  
Facilitate future research on stored specimens 
or additional measurements. 
To further characterize HIV disease in the 
study population 
 
Appendix C. Internalized AIDS-Related Stigma Scale 
The 6 items included in the Internalized AIDS-Related Stigma Scale are as follows. Responses 
are dichotomous (Agree/Disagree). 
1. It is difficult to tell people about my HIV infection. 
2. Being HIV positive makes me feel dirty. 
3. I feel guilty that I am HIV positive. 
4. I am ashamed that I am HIV positive. 
5. I sometimes feel worthless because I am HIV positive. 
6. I hide my HIV status from others. 
 
From Kalichmana, S.C., et al., Measuring AIDS stigmas in people living with HIV/AIDS: the Internalized AIDS-
Related Stigma Scale. AIDS Care, 2009. 21(1): p. 87-93. 
 
Primary Objectives: Secondary Objectives: 
Study Design:
• Study design
– This is a natural history study of individuals currently 
receiving or initiating care for HIV infection.
• Study setting:
– Montserrado and Margibi County
– JFK IDC, CH Rennie, Duport Road, Redemption, 
• Population:
– People living with HIV initiating
– N=3,500
▪ Inclusion Criteria
▪ Adults and children with confirmed HIV infection
▪ Ability and willingness to provide informed consent
▪ Willingness to allow storage of biological samples for future 
research
▪ Willingness to be referred for clinical care (if not already in care)
▪ Exclusion criteria:
▪ Any condition that, in the opinion of the investigator, would 
compromise the safety of the study subject or staff, or would 
prevent proper conduct of the study.
HONOR Study Inclusion/Exclusion Criteria
▪ Individuals will be enrolled at HIV clinics affiliated with 
PREVAIL sites, starting at JFK Hospital (2,300 PLHIV)
▪ Enrollment will proceed sequentially at other PREVAIL sites in 
absence of unforeseen operational impediments to implementation.
▪ Recruitment from other networks and groups
▪ Individuals enrolled at HIV clinics affiliated with PREVAIL
▪ From within PREVAIL studies
▪ National HIV counseling/testing and treatment centers
▪ HIV support groups/other informal associations
▪ SMC
▪ Study information will be disseminated through patient networks
Recruitment and Retention Plans
Schedule of Procedures and Evaluations 
 
Abbreviations: ART, antiretroviral therapy; CBC, complete blood count; CRF, case report form; HBV, hepatitis B virus; HIV, human immunodeficiency virus; IL, interleukin; NAT, nucleic acid test; 
PBL, peripheral blood leukocyte; PT/PTT, prothrombin time/partial thromboplastin time; TB, tuberculin; VL, viral load; WHBL, whole blood. 
a Subjects with a new HIV diagnosis only. 
   
b Body temperature, blood pressure, heart rate, respiratory rate, oxygen saturation, and weight. 
   
c Participants <18 years of age only. 
d Participants ³12 years of age only. 
e Participants ³18 years of age only. 
   
f Chest x-ray will be performed in lieu of TB skin test for participants who received Bacillus Calmette–Guérin (BCG) vaccine in infancy and are ≤18 years of age at enrollment and for those who 
received BCG in adulthood ≤10 years prior to enrollment. Participants receiving the TB skin test will return to have the test read 48 to 72 hours after placement. 
g By ELISA and Western blot or by HIV-1 RNA. Subjects will receive pre- and post-test counseling. 
   
h Dip stick for qualitative glucose, protein, pH, specific gravity. 
   
i Sodium, potassium, chloride, total carbon dioxide, creatinine, glucose, urea nitrogen, estimated glomerular filtration rate, albumin, calcium, magnesium, phosphorus, alkaline phosphatase, alanine 
and aspartate transaminase, total and direct bilirubin, C-reactive protein, amylase, and lipid panel. 
j Includes hepatitis B surface antigen, core antibody, e antigen, surface antibody, and viral load. 
   
k Evaluations will not be repeated if previously resulted as positive. 






















































































































Eligibility assessment X X
Physical exam (focused, symptom-directed) X X X X X X X X X
Vital signsa X X X X X X X X X X
Height X Xb Xb Xb Xb Xb Xb Xb Xb
Medical history X X X X X X X X X
Medication history X X X X X X X X X
Behavioral risk assessmentc X X X X X X X X X
ART counseling (subjects taking or 
beginning ART)
X X X X X X X X
Internalized AIDS-Related Stigma Scaled X X X X X
Complete CRFs X X X X X X X X X X
Clinical Laboratory Evaluations
HIV-1/2 testing Xe
Urine pregnancy test (women of childbearing 
potential)
X X X X X X X X X
Urinalysisf X X X X X X X X X
Gonorrhea, chlamydia, urine NATc X X X X
CBC with differential X X X X X X X X X X
PT/PTT, d-dimer X X X X X X X X X
Chemistryg X X X X X X X X X
WHBL (CD4, T cell, flow cytometry) X X X X X X X X X
HIV-1 pVL X X X X X X X X X
Syphilisc X X X X
HBV (antibody, antigen)h X Xi Xi Xi
Interferon gamma release assay X X X X
Research Laboratory Evaluations
IL6, serum X X X X
Plasma storage X X X X X X X X X
Serum storage X X X X X X X X X
PBL storage X X X X
▪ Information sessions facilitated by use of illustrated flip books to enhance 
individuals’ understanding of the study requirements, risks, and benefits. 
▪ Participants will sign/mark the informed consent document before any study 
procedures are performed. 
▪ The participants may withdraw consent at any time throughout the course of the 
study. 
▪ The rights and welfare of the participants will be protected by emphasizing that 
they will continue to receive medical care if they decline to participate.
▪ Informed consent of children less than 18 years of age:
▪ Provided by parent or legal representative 
▪ Participants 8-17 years old will also provide assent in addition. Without assent the 
participant will not be enrolled.
HONOR: Informed Consent/Assent
Statistical Analysis Plan
▪ Estimate the prevalence and incidence of various outcomes of HIV 
infection in the cohort and for various subgroups. 
▪ Sample proportions and 95% confidence intervals [15]
▪ Test if certain participant characteristics are risk factors for a collection of 
outcomes
▪ Chi-squared tests or Fisher’s exact test 
▪ Logistic regression to control for potential confounders, such as age and 
CD4 levels. 
▪ Kaplan-Meier curves and the log rank test
▪ Cox models and their modifications to conduct adjusted analyses that 
control for potential confounders. 
▪ All analyses will use a significance level of 0.05, but all results will be 
reported. 
▪ Power of the study design: With 3,500 participants, the standard error 
associated with a sample proportion is less than 0.009, which gives a margin of 
error less than 0.017 so that 95% confidence intervals for prevalence and 
incidence estimates will have a maximal width less than 0.04. These constitute 
precise estimates. 
Statistical Analysis Plan
▪ Estimates for sub-groups would have less precision depending on the size of the subgroup. 
Estimates for subgroups which comprise at least 20% of the study population will have precise 
estimates (i.e., the total width of a 95% confidence interval will be less than 0.1), whereas 
subgroups which comprise less than 5% of the study population will have wide confidence 
intervals (i.e., the total width of a 95% confidence interval will approach 0.15).
▪ The power to find an association between a risk factor and an outcome depends on the 
frequency of the risk factor and outcome and the magnitude of the association between 
the risk factor and outcome.
▪ To detect associations as weak as a relative risk of 1.5, the outcome prevalence would 
need to exceed 10% for a risk factor which is found in half the sample to have acceptable 
(i.e., 80%) power. 
▪ For stronger associations, we will have acceptable power for less common outcomes and 
risk factors. While these results are stated in terms of a prevalence, similar reasoning holds 
for outcomes that are observed longitudinally and would better be described as an 
incidence. For example, if the outcome was progression to AIDS and the risk factor was a 
baseline risk factor (e.g., MSM) these same calculations apply. 
Statistical Analysis Plan
▪ Power of time to event analyses (Table 2). We assume that a 
certain proportion have a risk factor and we observe a certain 
number of events. 
▪ We can use Freedman’s formula to compute the power as it 
depends on the number of events (using the expected number of 
events given the sample size and outcome prevalence), the 
relative size of the at risk group (using the expected sizes using 
the risk factor prevalence and sample size), and the hazard ratio 
(using the inverse of the relative risk). Comparison of the Tables 
1 and 2 indicates that there is more power associated with the 
time to event analysis, especially as the risk factor prevalence 
increases. 
▪ Participants will continue to receive medical care and 
treatment, including ART provision and management, 
from local clinicians according to local care 
standards or be enrolled in care.
▪ Patients not already enrolled in care will be enrolled 
in care
▪ The study team will share results of all clinical tests 




▪ Conducted under the direction of a protocol team  
▪ Data collection plans may be modified; new sub-studies may be planned.
▪ Risks of study participation will be minimal:
▪ Blood draw: transient pain, bleeding, bruising, light headedness, etc. 
▪ Blood: Adult: 10.5 mL/kg, max. 550 mL; Child: 5mL/kg/visit, max. 9.5 mL/kg over 8 
visits.
▪ PI discretion to limit these volumes in any participant whose clinical condition might 
be adversely affected.
▪ Loss of confidentiality (staff and trackers will be trained)
Overview of Operational Plan
▪ Research-related interventions include blood drawing 
and TB skin testing. 
▪ Only AEs occurring within 48 hours of the research 
procedures and assessed by site investigator as 
possibly, probably or definitely related will be 
recorded on the CRF, reviewed by the PI, reported 
following NIAID IRB and NREB reporting 
requirements, and followed through resolution by the 
PI. 
▪ No other medical occurrence will be considered an 
AE for this study.
Safety Assessment
▪ Storage and Tracking
▪ All samples and data will be stored in locked freezers in the 
PREVAIL Repository and rooms in Liberia. 
▪ All samples and data will be stored using ID codes.
▪ Password-protected computers will be used plus limited access.
▪ Disposition of and use of stored samples
▪ NIAID IRB and NREB approval will be sought before sharing any 
sample/data with new collaborators.
▪ Some exemptions from the need for approval might apply. 
▪ At completion of study, samples will either be destroyed or 
banked/transferred to another protocol (this will require 
IRB/NREB approval).
Sample Storage, Use and Sharing
▪ Local Review and approval of Protocol and Informed Consent by 
IRB/NIAID and NREB
▪ Ethical Conduct of the Study according to:
▪ Declaration of Helsinki US regulations protecting of human subjects 
such as 45 CFR 46
▪ Requirements of Good Clinical Practice (GCP)
▪ US Office for Human Research Protections (OHRP)
▪ Laws governing research and rights of human subjects in Liberia
▪ Confidentiality of study participants
▪ The confidentiality of all study participants will be protected in accordance 
with GCP Guidelines and national regulations.
▪ Compensation
▪ Participants will be compensated $10 at each research visit, when 
specimens are collected, for their time and inconvenience.
Ethical Conduct and Compensation
Challenges
• Stigma associated with the disease
• Fatality rate
• Confidentiality
• Enrolling children
